1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Anika Therapeutics, Inc.

Anika Therapeutics, Inc.

ANIK
Anika Therapeutics, Inc.US flagNASDAQ Global Select
14.74
USD
+0.02
- -
196.12MMarket Cap

Total Valuation

Anika Therapeutics, Inc. carries a market capitalization of 196.12M, placing it among publicly traded companies globally. Its enterprise value stands at 189.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap196.12M
Enterprise Value189.84M

Share Statistics

Anika Therapeutics, Inc. currently has 13.36M shares outstanding.

Shares Outstanding13.36M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.76, and the price-to-book ratio stands at 3.67.

PE RatioN/A
PS Ratio1.76
PB Ratio3.67
P/TBV Ratio1.65
P/FCF Ratio17.40
P/OCF Ratio31.69

Enterprise Valuation

On an enterprise value basis, Anika Therapeutics, Inc. trades at an EV/EBITDA multiple of 10.64 and an EV/FCF ratio of 15.95. The EV/Sales ratio of 1.63 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.49 provides insight into valuation relative to core operating earnings.

EV / Sales1.63
EV / EBITDA10.64
EV / EBIT15.49
EV / FCF15.95

Financial Position

Anika Therapeutics, Inc. maintains a current ratio of 4.46, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

Current Ratio4.46
Quick Ratio3.19
Debt / Equity19.22
Debt / EBITDA-3.83
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-18.02
Return on Assets (ROA)-5.98
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.18

Taxes

Income Tax818,000.00
Effective Tax RateN/A

Stock Price Statistics

Anika Therapeutics, Inc.'s stock has gained approximately 32.67327% over the past 52 weeks. The 50-day moving average sits at 14.87, while the 200-day moving average is 11.47.

Beta (5Y)N/A
52-Week Price Change32.67327%
50-Day Moving Average14.87
200-Day Moving Average11.47
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Anika Therapeutics, Inc. generated 116.26M in revenue and converted that into -11.06M in net income, yielding earnings per share of -0.78. EBITDA reached -6.71M, while operating income came in at -12.25M.

Revenue116.26M
Gross Profit68.12M
Operating Income-12.25M
Pretax Income-10.26M
Net Income-11.06M
EBITDA-6.71M
EBIT-12.25M
Earnings Per Share (EPS)-0.78

Balance Sheet

Anika Therapeutics, Inc. holds 41.02M in cash and equivalents against 25.74M in total debt, resulting in a net debt position of -41.02M. Total book value stands at 55.86M, with working capital of 72.60M providing operational flexibility.

Cash & Cash Equivalents41.02M
Total Debt25.74M
Net Debt-41.02M
Equity (Book Value)55.86M
Book Value Per Share3.95
Working Capital72.60M

Cash Flow

Anika Therapeutics, Inc. produced 6.47M in operating cash flow over the past twelve months. After subtracting -5.43M in capital expenditures, free cash flow totaled 1.04M - equivalent to 0.07 per share.

Operating Cash Flow6.47M
Capital Expenditures-5.43M
Free Cash Flow1.04M
FCF Per Share0.07

Margins

Anika Therapeutics, Inc. operates with a gross margin of 58.59, reflecting its pricing power and cost economics. The operating margin of -10.54 and net profit margin of -9.52 provide insight into operational efficiency.

Gross Margin58.59
Operating Margin-10.54
Pretax Margin-8.82
Profit Margin-9.52
EBITDA Margin-5.77

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield7.54
FCF Yield5.75

Scores

Anika Therapeutics, Inc. posts an Altman Z-Score of 4.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.12